In the near future, patients with relapsed lymphoma can likely enrol in a formal clinical trial that will personalise the most effective cocktail of drugs to treat their disease based on calculations done by an artificial intelligence (AI) platform. Led by Dr Anand Jeyasekharan and A/Prof Edward Chow (Department of Pharmacology) from the NUS Centre for Cancer Research (N2CR) and Cancer Science Institute of Singapore, a study on 17 patients who had suffered multiple lymphoma relapses saw significant improvement in eight of them after they took a cocktail of medication recommended by the platform. Of these eight patients, five had their cancer completely eradicated.